Steer C J, Kusiak J W, Brady R O, Jones E A
Proc Natl Acad Sci U S A. 1979 Jun;76(6):2774-8. doi: 10.1073/pnas.76.6.2774.
Intravenously administered (125)I-labeled human beta-hexosaminidase A (beta-N-acetylglucosaminidase; 2-acetamido-2-deoxy-beta-D-glucoside acetamidodeoxyglucohydrolase, EC 3.2.1.30) was rapidly cleared from the circulation of rats and accumulated in the liver. When hepatic cells were subsequently isolated, the label was recovered from both sinusoidal cells and, to a lesser extent, hepatocytes. Clearance was inhibited by the simultaneous infusion of mannan but not by a galactose-terminated glycoprotein. Studies in vitro, in which (125)I-beta-hexosaminidase was incubated with isolated hepatic cells, detected no uptake of the labeled ligand by hepatocytes. In contrast, uptake by sinusoidal cells was shown to be temperature dependent and approached saturability. Prior treatment of sinusoidal cells with Pronase resulted in markedly decreased uptake of (125)I-beta-hexosaminidase by these cells. Mannan and partially deglycosylated glycoproteins bearing terminal nonreducing N-acetylglucosamine or mannose residues were shown to be potent inhibitors of the cellular uptake of (125)I-beta-hexosaminidase; native orosomucoid and desialylated (galactoseterminated) orosomucoid were not inhibitory. Of six simple sugars tested, including N-acetylglucosamine, only mannose was an effective inhibitor of the cellular uptake of (125)I-beta-hexosaminidase. The kinetics of uptake of beta-hexosaminidase and mannose-terminated orosomucoid by sinusoidal cells were shown to be similar. These findings suggest that the hepatic uptake of the lysosomal glycosidase beta-hexosaminidase A is mediated by a receptor on sinusoidal cells which recognizes and binds mannose-terminated glycoproteins.
静脉注射(125)I标记的人β-己糖胺酶A(β-N-乙酰氨基葡萄糖苷酶;2-乙酰氨基-2-脱氧-β-D-葡萄糖苷乙酰氨基脱氧葡萄糖水解酶,EC 3.2.1.30)后,其在大鼠循环系统中迅速清除,并在肝脏中蓄积。随后分离肝细胞时,在窦状细胞以及程度较轻的肝细胞中均发现了放射性标记。同时输注甘露聚糖可抑制清除,但半乳糖末端糖蛋白则无此作用。在体外实验中,将(125)I-β-己糖胺酶与分离的肝细胞一起孵育,未检测到肝细胞对标记配体的摄取。相反,窦状细胞的摄取显示出温度依赖性且接近饱和。用链霉蛋白酶预先处理窦状细胞会导致这些细胞对(125)I-β-己糖胺酶的摄取明显减少。带有末端非还原型N-乙酰氨基葡萄糖或甘露糖残基的甘露聚糖和部分去糖基化糖蛋白被证明是(125)I-β-己糖胺酶细胞摄取的有效抑制剂;天然血清类黏蛋白和去唾液酸化(半乳糖末端)血清类黏蛋白无抑制作用。在所测试的六种单糖中,包括N-乙酰氨基葡萄糖,只有甘露糖是(125)I-β-己糖胺酶细胞摄取的有效抑制剂。窦状细胞对β-己糖胺酶和甘露糖末端血清类黏蛋白的摄取动力学显示相似。这些发现表明,溶酶体糖苷酶β-己糖胺酶A的肝脏摄取是由窦状细胞上的一种受体介导的,该受体识别并结合甘露糖末端糖蛋白。